Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. A nationwide analytical and clinical evaluation of 44 rapid antigen tests for SARS-CoV-2 compared to RT-qPCR

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The challenges of defining sample adequacy in an era of HPV based cervical screening

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Aseptic meningitis outbreak associated with echovirus 4 in Northern Europe in 2013-2014

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Neutralization and receptor use of infectious culture-derived rat hepacivirus as a model for HCV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. An Adaptable Platform for in-house Hepatitis C Serology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Protection against SARS-CoV-2 transmission by a parenteral prime-Intranasal boost vaccine strategy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Chronic hepatitis B virus (HBV) treatment consists of nucleos(t)ide analogues to suppress viral replication. The HBV inhibitor tenofovir has a high barrier to resistance, however, evidence of virus-escape is emerging. This study investigates HBV evolution in patients undergoing tenofovir treatment with the primary aim to assess the emergence of putative resistance mutations.

METHODS: HBV DNA was extracted from blood samples of two patients with HBeAg-positive chronic HBV infection and persistent viremia despite tenofovir treatment, and subsequently amplified by PCR before full-length HBV genomes were assembled by deep sequencing. The mutation linkage within the viral population was evaluated by clonal analysis of amplicons.

RESULTS: Sequence analysis of HBV, derived from 11 samples collected 2010-2020 from one patient, identified 12 non-synonymous single-nucleotide polymorphisms (SNPs) emerging during a tenofovir treatment interruption from 2014 to 2017. Two of the SNPs were in the reverse transcriptase (RT; H35Q and D263E). The two RT mutations were linked and persisted despite restarting tenofovir treatment in 2017. For the second patient, we analyzed HBV derived from six samples collected 2014-2020 following 10 years of tenofovir treatment, and identified five non-synonymous SNPs, that confer resistance towards entecavir and/or lamivudine. Two RT mutations (H35N and P237T) emerged during subsequent 5-year entecavir treatment. H35N was maintained during final tenofovir treatment.

CONCLUSIONS: Our findings indicate that changes at the conserved residue 35 (H35N/Q) in the HBV RT may be associated with tenofovir resistance. These variants have not previously been described, and further studies are warranted to assess resistance in vitro and in vivo.

OriginalsprogEngelsk
Artikelnummer105159
TidsskriftJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Vol/bind150-151
ISSN1386-6532
DOI
StatusUdgivet - jun. 2022

Bibliografisk note

Copyright © 2022. Published by Elsevier B.V.

ID: 77845098